Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal wit | Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now,
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...
Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and ...
Hosted on MSN16d
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, ...
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback